6,846 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by Kennebec Savings Bank

Kennebec Savings Bank purchased a new position in Johnson & Johnson (NYSE:JNJ) during the 3rd quarter, Holdings Channel.com reports. The firm purchased 6,846 shares of the company’s stock, valued at approximately $1,109,000. Johnson & Johnson makes up about 1.1% of Kennebec Savings Bank’s holdings, making the stock its 25th biggest position.

Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Ashton Thomas Securities LLC purchased a new stake in Johnson & Johnson during the 3rd quarter valued at $713,000. Intrinsic Value Partners LLC purchased a new stake in Johnson & Johnson during the 3rd quarter valued at $206,000. 1900 Wealth Management LLC boosted its stake in Johnson & Johnson by 6.1% during the 3rd quarter. 1900 Wealth Management LLC now owns 6,621 shares of the company’s stock valued at $1,047,000 after purchasing an additional 382 shares during the last quarter. Tyler Stone Wealth Management boosted its stake in Johnson & Johnson by 104.3% during the 3rd quarter. Tyler Stone Wealth Management now owns 6,308 shares of the company’s stock valued at $1,022,000 after purchasing an additional 3,220 shares during the last quarter. Finally, Baker Avenue Asset Management LP boosted its stake in Johnson & Johnson by 45.1% during the 3rd quarter. Baker Avenue Asset Management LP now owns 15,557 shares of the company’s stock valued at $2,521,000 after purchasing an additional 4,838 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. The Goldman Sachs Group cut their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Guggenheim increased their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, TD Securities lowered their price target on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $175.00.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $155.05 on Tuesday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The business’s 50-day simple moving average is $162.61 and its two-hundred day simple moving average is $155.91. The stock has a market cap of $373.30 billion, a PE ratio of 22.44, a P/E/G ratio of 2.76 and a beta of 0.53. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.66 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.20%. Johnson & Johnson’s payout ratio is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.